Highly interesting events on transglutaminase, celiac disease, thromoprophylaxis or other related topics.
Please contact us in advance to make an appointment to meet at the venue.



27th ISTH Congress
06. July 2019 - 10. July 2019

Location Melbourne, Australia
External Link ISTH
Comment Meet the leading experts at the International Society on Thrombosis and Haemostasis (ISTH) congress.
 
 
18th International Celiac Disease Symposium ICDS
04. September 2019 - 07. September 2019

Location Paris, France
External Link ICDS
Comment The 18th ICDS will bring together the leaders in celiac disease research.
 
 
European Congress on Thrombosis and Haemostasis
02. October 2019 - 04. October 2019

Location Glasgow, United Kingdom
External Link ECTH 2019
Comment Learn more about advancement of Thrombosis and Haemostasis and discuss developments with researchers and healthcare professionals from across Europe.
 
 
Celiac Disease Center's International Symposium
06. March 2020 - 07. March 2020

Location New York, USA
External Link calendar
Comment Join an international symposium organized by the Celiac Disease Center at Columbia University.
 
 
Gordon Research Conference - Transglutaminases in Human Disease Processes
14. June 2020 - 19. June 2020

Location Mount Snow, USA
External Link GRC
Comment Meet Dr. Ralf Pasternack and Dr. Martin Hils at the venue.
 
 

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Team-Assistenz (w/m/d) in Teilzeit gesucht
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • 27th ISTH Congress

    06.07.2019 - 10.07.2019
    Melbourne, Australia

  • 18th International Celiac Disease Symposium ICDS

    04.09.2019 - 07.09.2019
    Paris, France

  • European Congress on Thrombosis and Haemostasis

    02.10.2019 - 04.10.2019
    Glasgow, United Kingdom

  • Celiac Disease Center's International Symposium

    06.03.2020 - 07.03.2020
    New York, USA

  • Gordon Research Conference - Transglutaminases in Human Disease Processes

    14.06.2020 - 19.06.2020
    Mount Snow, USA